肾乐胶囊对大鼠5/6肾切除肾衰模型作用机理的实验研究被引量：6

Curative machanism of Shenle capsule on 5/6 nephrectomy rats

在线阅读下载PDF

导出

摘要目的 :通过对大鼠 5 / 6肾切除 (5 / 6NX)所致肾衰模型的研究 ,探讨中药复方肾乐胶囊治疗慢性肾衰的作用机理。方法 :采用纤维蛋白原平板溶环法 ,检测尿中纤溶酶原激活物PA的活性 ;用半定量法分析残肾组织中组织型纤溶酶原激活物 ,尿激酶型纤溶酶原激活物 /纤溶酶原激活物抑制物 (tPA ,uPA/PAI 1)的染色强度和面积 ;用Northernblot来观察转化生长因子β(TGF β)mRNA的表达。结果 :模型对照组大鼠尿PA活性下降 ,肾组织tPA ,uPA表达下降 ;而肾组织中PAI 1和TGF βmRNA表达增高。肾乐胶囊治疗后 ,尿PA的活性升高 ,肾组织中tPA ,uPA的表达增强 ;而肾组织中PAI 1和TGF βmRNA的表达却下降。结论 :肾乐胶囊可以通过调节 5 / 6NX模型大鼠尿PA的活性 ,肾组织tPA ,uPA/PAI 1,TGF βmRNA的表达。 Objective: To explore curative machanism of Shenle capsule on the 5/6 nephrectomy rats. Method: Fibrin plate method was applied to examine activity of urinary plasminogen activator(PA). Semi-quantitative analysis was used to observe stained intensity and area of tissue-type plasminogen activator, urokinas-type plasminogen activator/ plasminogen activator inhibitor(tPA, uPA/PAI-1)in remnant renal tissue. Northern blot was employed to analyze the expression of transforming growth factor (TGF-β)mRNA. Result: In model control group,the urinary PA activity and protein expression of tPA, uPA were down-regulated, but protein expression of PAI-1, TGF-β mRNA was up-regulated in remnant renal tissue. In each treated group, the urinary PA activity and protein expression of tPA/uPA were enhanced,but the protein expression of PAI-1, TGF-βmRNA decreased simultaneously. Conclusion: Shenle capsule can delay glomerulosclersis and tubulointerstitial fibroticlesions of remnant kidney by improving the activity of urinary PA and modulating the expression of tPA,uPA/PAI-1 and TGF-βmRNA.

作者魏日胞张五星陈香美

机构地区解放军总医院肾科解放军肾病中心暨重点实验室

出处《中国中药杂志》 CAS CSCD 北大核心 2004年第8期770-773,共4页 China Journal of Chinese Materia Medica

基金国家"十五"科技攻关课题 ( 2 0 0 1BA70 1A14a)

关键词肾组织 PAI-1 TGF-Β 胶囊表达大鼠肾衰活性增强研究 Shenle capsule plasminogen activator(PA) I-type plasminogen activator inhibitor(PAI-1) transforming growth factor(TGF-β)

分类号 R285.5 [医药卫生—中药学]

引文网络
相关文献

参考文献9

1[1]Stemer G, Wennberg A. Partial nephrectomy and chronic renal failure the "adult"rat model. Contr Nephot, 1988,60:39.
2[3]Fine L G, Onga C M, Norman J T. Mechanisms of tubulointerstitial injury in progressive renal disease. Eur J Clin Invest ,1993 , 23:259.
3[4]OikawaT, Freeman M, LoW, etal. Modulatinn ofplasminogen activator inhinbitor-1 in vivo: a new mechanism for the anti-fibrotic effect of rennin-angiotensin inhibition. Kidney Int, 1997, 51: 164.
4[5]Mignatti P. Extracellular matrix remodeling by metallopro-teinases and plasminogen activators. Kidney Int, 1995, 47(suppl): S12.
5[6]Malliaros J, Holdsworth S R, Wojta J, et al. Glomerular fibri-nolytic activity in anti-GBM glomerulonephritis in rabbits. Kidney Int, 1993,44:557.
6[7]Shihab F B, Bennett W M, Tanner A M, etal. Angintensin blockade decreases TGF-beta 1 and matirx proteins in cy-closporine nephropathy. Kidney Int, 1997,52 (3) :660.
7[8]Inagaki Y, Truter S, Tanaka S, et al. Overlapping pathways mediate the opposing actions of TNF alpha and TGF beta onalpha2 collagen transcription. J Biol Chem, 1995, 270(7): 353.
8[9]Ziyadeh F N, Han D C. Involvement of transformation growth factorband its receptor in the pathogenesis of diabetic nephropathy. KidneyInt, 1997,52:S7.
9[10]Tomooka S, Border W A, Marshall B C, et al. Glomerular ma-trixaccumulaton is linked to inhibition ofthe plasmin proteasesystem.Kidney Int, 1992,42:1462.